Literature DB >> 6362876

Molecular and biochemical pharmacology of mitoxantrone.

F E Durr, R E Wallace, R V Citarella.   

Abstract

Evidence has been presented which indicates that Nv: intercalates DNA and additionally causes inter- and intra-strand crosslinking possibly associated with its charged side arms; there is an apparent preference for G-C base pairs; induces single strand and double strand breaks in DNA; strongly inhibits DNA and RNA synthesis; causes nuclear aberrations and chromosomal scattering; induces a block in the G2 phase of the cell cycle with an increase in cellular RNA and polyploidy; is not cell cycle phase-specific with respect to cell kill; does not induce free-radical formation; does not induce lipid peroxidation or superoxide formation; rather it may inhibit ADR-stimulated lipid peroxidation and microsomal superoxide production; does not appear to have a strong potential for cardiotoxicity on the basis of currently postulated mechanisms of action; is capable of inducing cellular resistance in vitro; resistance is associated with an apparent alteration in the cell membrane impairing drug transport into the cell. Although the precise mechanism(s) of tumor cell killing has not been fully defined it is most likely associated with an interaction by Nv with chromosomes resulting in DNA damage, which if not efficiently repaired, will lead to inhibition of nucleic acid synthesis and eventual cell death.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6362876     DOI: 10.1016/0305-7372(83)90016-6

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  21 in total

1.  Nucleotide excision repair polymorphisms and survival outcome for patients with metastatic breast cancer.

Authors:  Mary A Bewick; Robert M Lafrenie; Michael S C Conlon
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-28       Impact factor: 4.553

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Short-chain glycoceramides promote intracellular mitoxantrone delivery from novel nanoliposomes into breast cancer cells.

Authors:  Lília R Cordeiro Pedrosa; Timo L M Ten Hagen; Regine Süss; Albert van Hell; Alexander M M Eggermont; Marcel Verheij; Gerben A Koning
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

4.  Overadditive synergism between the intercalators mitoxantrone and lucanthone in advanced L 12010 and P 388 leukemia.

Authors:  H Osswald; M Youssef
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

5.  A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding.

Authors:  Guohua An; Marilyn E Morris
Journal:  AAPS J       Date:  2012-03-27       Impact factor: 4.009

6.  Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment.

Authors:  Lubing Gu; Hailong Zhang; Tao Liu; Sheng Zhou; Yuhong Du; Jing Xiong; Sha Yi; Cheng-Kui Qu; Haian Fu; Muxiang Zhou
Journal:  Cancer Cell       Date:  2016-09-22       Impact factor: 31.743

7.  Pharmacology of mitoxantrone: mode of action and pharmacokinetics.

Authors:  D S Alberts; Y M Peng; G T Bowden; W S Dalton; C Mackel
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

8.  A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck.

Authors:  H Wheeler; R L Woods; J Page; J Levi
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

9.  A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol.

Authors:  J P Laporte; N C Gorin; M P Lemonnier; F Isnard; A Najman
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone.

Authors:  D Baker; J K O'Neill; A N Davison; J L Turk
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.